Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program

Journal:
Journal of Hepatology
Published:
Affiliations:
34
Authors:
46
Institutions Authors Share
Unité Mixte de Recherche Physiopathologie et Traitement des Maladies Hépathiques (PaThLiv), France
4.000000
0.09
Medical University of Vienna (MUW), Austria
3.000000
0.07
Hôpital Avicenne, France
3.000000
0.07
Replicor, Canada
2.000000
0.04
Clinique l'Agora, Canada
2.000000
0.04
Ciblage Individuel et Prévention des Risques en Transplantation (IPPRITT), France
2.000000
0.04
Montpellier University Hospital, UM, France
2.000000
0.04
AP-HP Beaujon Hospital, France
2.000000
0.04
Hôpital Rangueil, CHU-Toulouse, France
2.000000
0.04
Soroka Medical Center, Israel
2.000000
0.04
Koç University (KU), Turkey
2.000000
0.04
Centre Hospitalier de Perpignan, France
2.000000
0.04
Hôpital Saint Joseph - Marseille, France
1.500000
0.03
Economic and Social Sciences, Health Systems and Medical Informatics (SESSTIM), France
1.500000
0.03
University of Rome Tor Vergata, Italy
1.000000
0.02
Bichat-Claude Bernard Hospital, France
1.000000
0.02
CHU Henri-Mondor, France
1.000000
0.02
Westmead Hospital (WSLHD), Australia
1.000000
0.02
The University of Sydney (USYD), Australia
1.000000
0.02
Westmead Institute for Medical Research, Australia
1.000000
0.02
Centre Hospitalier de Versailles (CHV), France
1.000000
0.02
Centre Hospitalier Universitaire de Lille (CHU Lille), France
1.000000
0.02
Rennes University Hospital (CHU Rennes), France
1.000000
0.02
University of Padova (UNIPD), Italy
1.000000
0.02
Link Campus University, Italy
1.000000
0.02
University of Campania Luigi Vanvitelli, Italy
1.000000
0.02
Loyola University Chicago (LUC), United States of America (USA)
1.000000
0.02
Prof. Dr. Cemil Taşçıoğlu City Hospital, Turkey
1.000000
0.02
University Medical Center Freiburg, Germany
0.500000
0.01
University Hospital of Cologne, Germany
0.500000
0.01